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In spite of the success of genome-wide association studies (GWASs), only a small proportion of heritability for each complex trait has
been explained by identified genetic variants, mainly SNPs. Likely reasons include genetic heterogeneity (i.e., multiple causal genetic
variants) and small effect sizes of causal variants, for which pathway analysis has been proposed as a promising alternative to the stan-
dard single-SNP-based analysis. A pathway contains a set of functionally related genes, each of which includes multiple SNPs. Here we
propose a pathway-based test that is adaptive at both the gene and SNP levels, thus maintaining high power across a wide range of
situations with varying numbers of the genes and SNPs associated with a trait. The proposed method is applicable to both common
variants and rare variants and can incorporate biological knowledge on SNPs and genes to boost statistical power. We use extensively
simulated data and a WTCCC GWAS dataset to compare our proposal with several existing pathway-based and SNP-set-based tests,
demonstrating its promising performance and its potential use in practice.Introduction
Genome-wide association studies (GWASs) have been suc-
cessful in identifying many genetic variants, mainly SNPs,
associated with complex and common disease (see, for
example, the online Catalog of Published Genome-Wide
Association Studies). However, only a small proportion of
the estimated heritability for most human complex traits
can be explained by the identified genetic variants. One
possible reason is that, due to small effect sizes and genetic
heterogeneity (i.e., multiple causal variants), the standard
single-SNP-based analysis might not have enough power
to identify many causal variants. Although many human
genetic diseases are caused by variants in multiple genes,
it has been increasingly recognized that, because genomic
variants of these genes lead to the same or similar pheno-
types, these genes are likely to be functionally related,
and such functional relatedness can be exploited to iden-
tify novel genes containing variants related to disease.
One way to organize functionally related genes is through
biological pathways, such as annotated in the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) database.1 Associ-
ation analysis of multiple genes with related functions is
here generically called pathway analysis (or gene set anal-
ysis), which might improve power over testing on single
SNPs or single genes one by one. One convincing source
of evidence is from tumor sequencing studies, e.g., The
Cancer Genome Atlas (TCGA).2 Although a few genes
(e.g., TP53 [MIM: 191170]) harbor manymutations related
to cancer, most harbor few mutations in a tumor-depen-
dent way. For example, a tumor might contain mutations
in PTEN (MIM: 601728), not in NF1 (MIM: 613113),
whereas another tumor contains mutations in NF1, not
in PTEN. Individually, each of the genes in a related
pathway has only a low mutation frequency, but collec-1Division of Biostatistics, School of Public Health, University of Minnesota, M
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Hence, for a disease (e.g., cancer) involving a few path-
ways, a pathway analysis by aggregating information
across multiple genes in a relevant pathway will boost sta-
tistical power, and thus is preferred. For example, among
the 316 ovarian cancer (MIM: 167000) tumors studied by
TCGA, 45% of them had genomic alterations (somatic mu-
tations and DNA copy-number changes) in the PI3K/RAS
signaling pathway. This pathway contains seven genes—
PTEN, PIK3CA (MIM: 171834), AKT1 (MIM: 164730),
AKT2 (MIM: 164731), NF1, KRAS (MIM: 190070), and
BRAF (MIM: 164757)—each with only low to moderate
genomic alterations in 7%, 18%, 3%, 6%, 12%, 11%, and
0.5% of the tumors, respectively; hence, it should be
more powerful to detect genomic alterations at the
pathway level than at the individual gene level.
The importance of pathway analysis and many existing
approaches have been reviewed by several authors.3–5
Many pathway-based analysis methods for GWAS data
are evolved from those for gene expression data;6,7 how-
ever, higher-dimensional data are involved in the former
with up to hundreds to thousands of SNPs, compared to
only tens to hundreds of genes in the latter. On the other
hand, because it is known that not all the SNPs in any
gene or any pathway are related to a disease, statistically
it is most important and challenging to adaptively aggre-
gate information over multiple unknown causal SNPs
while minimizing the effects of non-causal SNPs. Existing
approaches have some limitations. For example, a popular
approach8 used the minimum p value of the multiple SNPs
in a gene to summarize association information for the
gene, which is not efficient if there are multiple weakly
associated SNPs inside the gene. Two other methods,
GATES-Simes9 and HYST,10 combine gene-level p values
based on GATES,11 a gene-based test using an extendedinneapolis, MN 55455, USA; 2Division of Biostatistics and Human Genetics
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Simes procedure to correct multiple testing while calcu-
lating the p value quickly and possibly based on SNP
summary statistics (instead of individual-level SNP and
phenotype data); GATES-Simes uses an extended Simes
procedure to extract the most significant gene-level p value
for a pathway, whereas HYST uses Fisher’s method to
combine multiple genes’ p values. Hence, as to be
confirmed later, GATES-Simes behaves like the minimum
p value method, losing power if there are multiple SNPs
and/or multiple genes with only weak association
strengths; in contrast, HYST, as Fisher’s method, is ex-
pected to be low powered if an increasing number of the
genes in a pathway are not associated with the trait.
A very recent approach12 uses a variance-component test
to aggregate information across multiple SNPs non-adap-
tively, which will lose power in the presence of many
non-associated genes. The fundamental problem is the
non-adaptive nature of these methods at both the SNP
and gene levels. Our proposal is based on a highly adaptive
test called adaptive sum of powered score (aSPU) test orig-
inally proposed for analysis of rare variants (RVs).13 The
main idea of the aSPU test is that, because we do not
know which and how many SNPs in the given set are asso-
ciated with a trait, we first construct a class of tests over-
weighting a sequence of increasingly smaller sets of the
top-ranked (i.e., most statistically significant) SNPs, then
select the test with the most significant result (with a
proper adjustment for multiple testing). For relatively
small sets of RVs, the aSPU test often outperforms other
tests.13 Here we extend the aSPU test to pathway analysis
of either common variants (CVs) or RVs. One change we
made is that, because the analysis unit of a pathway anal-
ysis is a gene but genes can contain quite different
numbers of SNPs, we need to modify the aSPU test to treat
each gene equally a priori. More importantly, the proposed
test is adaptive with respect to both genes and SNPs, which
is critical because we do not know a priori howmany genes
in a pathway are associated and how many SNPs in an
associated gene are associated with the given trait. We
will compare our proposal with two aforementioned
pathway-analysis methods, GATES-Simes and HYST, and
two other popular ones, one based on penalized regression
(called GRASS) and the other as a representative two-step
approach based on SNP screening then combining as
implemented in the software PLINK (called simply Plink
in the sequel),14,15 largely because the latter two methods
have been widely applied to GWASs in practice.16–18Material and Methods
Data and Notation
We consider the most popular case-control study design as adop-
ted inGWASs, though themethods can be extended to other study
designs, e.g., with a quantitative or survival trait. Suppose that for
subject i ¼ 1,.,n, Yi ¼ 0 or 1 is a binary trait, e.g., an indicator of
disease, and Xi ¼ (Xi1,., Xik)0 is the vector of the genotype scores
for k SNPs, possibly drawn from multiple genes in a pathway. WeThuse additive coding for each SNP; that is, Xij is the number of the
copies of an allele at SNP j for subject i. It is possible to include
other covariates, but for simplicity we ignore them. We consider
a logistic regression model:
Logit½PrðYi ¼ 1Þ ¼ b0 þ
Xk
j¼1
Xijbj: (Equation 1)
We’d like to test the null hypothesis H0 : b ¼ (b1,., bk)0 ¼ 0; that
is, there is no association between any SNPs and the trait underH0.
The score vector U¼ (U1,., Uk)0 for b and its covariance matrix are
U ¼
X
i
Xi

Yi  Y

;V ¼ CovðUÞ ¼ Y1 YX
i

Xi  X

Xi X
0
;
where Y and X are the sample means of Yis and Xis, respectively.
0 1The classic score test statistic is TScore ¼ U V U, which, however,
in the current context with a large k, relative to the sample size
n, might be low powered, as its asymptotically equivalent Wald
test and likelihood ratio test. As shown theoretically,19 as the
dimension k increases, the power of the score test might diminish,
tending to the type I error rate a. The most popular univariate sin-
gle SNP-based test, call UminP here, is TUminP ¼ maxkj¼1U2j =Vjj with
Vjj ¼ Var(Uj), which might also be low powered if we have many
small
bjs0. Two alternatives, called the Sum and SSU tests, are
TSum ¼ 10U
. ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
10V1
p
¼
Xk
j¼1
Uj
. ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
10V1
p
; TSSU ¼ U 0U ¼
Xk
j¼1
U2j :
The Sum test is powerful when all or most
bjs0 with the same
sign, but not otherwise. As shown by Pan,20 the SSU test can be re-
garded as a variance-component test21,22 and is closely related
to an empirical Bayes test for high-dimensional data23 and a
nonparametric MANOVA test.24 In particular, variance-compo-
nent tests, including kernel machine regression (KMR), have
been advocated for SNP set analysis and empirically shown to be
powerful in many cases.21,22,25 Nevertheless, as shown in Pan
et al.,13,26 because a variance-component test is not adaptive, in
the presence of many non-associated SNPs as anticipated in
the current context of pathway analysis, it might lose power.
Accordingly, a more powerful and adaptive test was proposed as
reviewed next.Review: The Data-Adaptive aSPU Test
Pan et al.13 proposed a class of sum of powered score (SPU) tests in
a different context for analysis of RVs:
TSPU ¼ TSPUðgÞðUÞ ¼
Xk
j¼1
Ugj : (Equation 2)
The SPU tests cover the Sum and SSU tests as two special cases
with a corresponding g ¼ 1 and g ¼ 2, respectively. Importantly,
as g / N (and as an even integer), then the SPU test would
approach the UminP test if the variances of the score compo-
nents are a constant (or if their varying variances are ignored,
which might be advantageous in certain cases); the reason is
simple:
kUkg ¼
 Xk
j¼1
jUj j g
!1=g
/kUkN ¼ max
j¼1
k jUj j ; as g/N:
Without covariates, we propose using permutations to obtain
p values. More generally, to adjust for covariates, the parametrice American Journal of Human Genetics 97, 86–98, July 2, 2015 87
bootstrap (or, alternatively, permuting residuals) can be used for
inference. Specifically, we will first fit a null model under H0,
then simulate a new set of traits Y(b)s from the fitted null model
for b ¼ 1,.,B; we calculate the test statistic T ðbÞSPU based on each
set of simulated Y(b); finally, we calculate the p value as
½PBb¼1IðTðbÞSPU RjTSPU jÞ þ 1=ðBþ 1Þ. We used B ¼ 500 in our simu-
lations for a nominal significance level at 5%.
There is no uniformly most powerful test in multilocus associa-
tion testing; on the other hand, it has been found empirically that
the Sum, SSU, and UminP tests performed well under different
situations. For a given dataset, to adaptively choose the value of
g for the SPU tests, Pan et al.13 propose an adaptive SPU (aSPU)
test that simply combines the results of multiple SPU tests:
suppose that we have some candidate values of g in G, e.g.,
G ¼ {1, 2, 3, ., 8} as used in our later experiments, and suppose
that the p value of the SPU(g) test is pg, then the aSPU test simply
takes the minimum p value:
TaSPU ¼ min
g˛G
pg:
Of course, TaSPU is no longer a genuine p value; we recourse to
the parametric bootstrap to estimate its p value. As before, first,
we simulate B independent copies Y(b) from the null distribution
of Y and obtain the null score vectors U(b) for b ¼ 1,2,.,B. We
then calculate the corresponding SPU test statistics T
ðbÞ
SPUðgÞ and
their p values p
ðbÞ
g ¼ ½
P
b1sb
IðTðb1ÞSPUðgÞRTðbÞSPUðgÞÞ þ 1=B. Thus, we
have T
ðbÞ
aSPU ¼ ming˛GpðbÞg , and the final p value of the aSPU test
PaSPU ¼ ½
PB
b¼1IðTðbÞaSPU%TaSPUÞ þ 1=ðBþ 1Þ.A Data-Adaptive Pathway-Based Test: aSPUpath
Given a pathway S with jSj genes, we partition the score vector
according to the genes as U ¼ ðU 01:;.;U 0jSj:Þ0 with the score subvec-
tor for gene g (with kg SNPs) as Ug: ¼ ðUg1;Ug2;.;Ugkg Þ0 based on
the logistic regression model (or other generalized linear models
or proportional hazards model). The gene-specific SPU statistic
and the pathway-based SPU statistic are, respectively,
SPU

g;wg ; g
 ¼ kUg:kg ¼
 Xkg
j¼1

wgjUgj
g
kg
!1=g
; (Equation 3)
PathSPUðg;gG;w;wG; SÞ ¼
X
g˛S

wG;gSPU

g;wg ; g
gG ; (Equation 4)
where two scalars g > 0 and gG > 0, gene-specific weights for SNPs
w ¼ ðw01; ::;w0jSjÞ0 and wg ¼ ðwg1;.;wgkg Þ0, and gene-specific
weights for genes wG ¼ ðwG;1;.;wG;jSjÞ0 are pre-specified. wg is
used to incorporate prior information on SNPs, e.g., to up-weight
SNPs associated with gene expression, whereaswG can be based on
gene functional annotations or gene expression data to represent
prior likelihoods of their being functional (and associated with the
trait); without prior knowledge or data, or for simplicity, we can
simply use wg ¼ 1 and wG ¼ 1, which are to be used by default un-
less specified otherwise in this paper. Note that SPU (g, wg; g) is
standardized by the gene-specific number of SNPs, kg, so that large
genes will not dominate a pathway analysis (since the genes in a
pathway are the analysis units and are thus treated equally a priori
if no weighting is desired). The intuition behind using gG is like
that for g: in general, a larger gG (or g) is more effective if there
are fewer associated genes (or SNPs) with larger effects in a
pathway (or in a gene), but not otherwise. Two extreme examples88 The American Journal of Human Genetics 97, 86–98, July 2, 2015are the following: (1) gG ¼ 1 (or g ¼ 1), treating all genes (or SNPs)
equally, which is most powerful if all the genes (or SNPs) are asso-
ciated with the trait with similar effect sizes and in the same direc-
tion (i.e., all positive or all negative); (2) gG ¼N (or g ¼N), using
only the most significant gene (or SNP) as the evidence against the
null hypothesis, which is most powerful if there are only one or
few genes (or SNPs) associated with the trait with a large effect
size. Between the two extremes, other values of gG (or g) might
be more powerful. For example, if only a subset of the genes (or
SNPs) are associated with different effect sizes and different direc-
tions, using gG¼ 2 (or g¼ 2) might be more powerful, as variance-
component tests (e.g., KMR); on the other hand, if the proportion
of the associated genes (or SNPs) decreases, a larger value, say
gG ¼ 4 (or g ¼ 4), might lead to a more powerful test; often
gG ¼ 8 or 16 (or g ¼ 8 or 16) gives the results similar to using
gG ¼N (or g ¼N). We also note that, if the association directions
of (most) associated genes (or SNPs) are in the same direction, us-
ing an odd integer of gG (or g) might be more powerful; otherwise,
using an even integer is more promising. These points have been
empirically verified for RV analysis13 and polygenic testing in
GWASs.26 In practice, because an optimal value of gG (or g) is un-
known, depending on the unknown genetic association patterns,
one has to conduct a grid search over a wide range of possible
values for gG (or g), but searching over toomany will introduce ex-
tra variability and thus lead to power loss. Based on our experience
coupled with the goal of a pathway-based analysis, to take advan-
tage of possibly multiple associated genes (and SNPs), we suggest
trying gG˛f1;2;4;8g (and g˛f1;2;3;.;8g) as shown in the results
below, though this needs to be further studied.
For any given (g,gG), as for SPU(g), we recourse to resampling to
calculate its p value PPathSPUðg;gG ;w;wG ;SÞ. Its power depends on the
choice of (g,gG). A pathway-based aSPU test is defined as
aSPUpathðSÞ ¼ min
g;gG
PPathSPUðg;gG ;w;wG ;SÞ; (Equation 5)
aiming to select from multiple PathSPU tests the most powerful
one. Similar to that for the aSPU test, we propose using a single
layer of the permutation or parametric bootstrap to calculate the
p values.
For the possible situation where multiple genes in a pathway
might contain quite different proportions of causal SNPs, we
might use a more general pathway-based test with a gene-specific
gg for each gene g. Denote g ¼ ðg1;.;gjSjÞ0, we can modify the
tests as
PathSPU2ðg;gG;w;wG; SÞ ¼
X
g˛S

wG;gSPU

gg ;wg ; g
gG ;
(Equation 6)
aSPUpath2ðSÞ ¼ min
g;gG
PPathSPU2ðg;gG ;w;wG ;SÞ: (Equation 7)
The corresponding aSPUpath2 test is computationally more
demanding in searching for suitable values of more parameters
in g and gG, which will also introduce more variability to the re-
sults and thus might lead to loss of power. This needs to be studied
further.Other Modifications
We also considered single-gene-based approaches and those based
on dimension reduction. Because they did not outperform the
proposed aSPUpath, we will present just a summary that might
be interesting.
Table 1. Empirical Type I Error Rates of the Tests for CVs
Set-up aSPUpath GRASS Plink aSPU SSU UminP GATES-Simes HYST
200 indep SNPs .055 .057 .02 .053 .046 .057 .047 .022
1,000 indep SNPs .048 .067 .03 .050 .052 .040 .040 .028
200 corr SNPs .054 .064 .05 .048 .040 .062 .050 .042As a representative of single gene-based approaches, we consid-
ered applying SPU and aSPU tests to each gene in a pathway, then
using the minimum gene-level p value as a final test statistic for
the pathway. It is easy to see that the pathway-based SPU(N) (after
ignoring the inverse weighting by the number of SNPs and the
possible use of weights) and single gene-based SPU(N) are almost
the same; hence, our proposed aSPUpath test is more adaptive and
thus expected to be more flexible and powerful.
For dimension reduction, as in GRASS, for each genewe replaced
its individual SNP genotype scores by their top few principal com-
ponents (PCs) that accounted for at least 95% of total variation,
and then we applied the pathway-based aSPU test to these PCs.
Perhaps due to the adaptivity of the original aSPUpath test and
possible loss of information by PCs, we did not find improvement
by the use of PCs in our simulations. However, given that PC-
based tests27,28 are viable competitors to variance-component tests
as discussed in Schaid et al.,12 we had an interesting, perhaps sur-
prising, observation: applying the SPU(2) (i.e., SSU) test (that is
equivalent to a variance-component test) to the original geno-
types or the PCs gave almost the same result; an explanation is
offered below.
Suppose that X is the n 3 k matrix of the original genotype
scores. We apply a singular value decomposition: XX
0 ¼ VL2V 0 ,
where we assume that the eigen values have been put in descend-
ing order as the diagonal elements ofL2. The first L PCs are the col-
umns of PL ¼ VLLL, where VL is an n 3 L matrix containing the
first L columns of V and LL is an L3 L diagonal matrix containing
the first L eigen values. Nowwe can compare the two SSU statistics
when applied to X and PL, respectively:
SSUðXÞ ¼ UðXÞ0UðXÞ ¼ Y  Y0XX0Y  Y0
¼ Y  Y0VLL0V 0Y  Y0
z

Y  Y0VLLLL0LV 0LY  Y0 ¼ SSUðPLÞ:
But for other g s 2, we would expect that, in general, SPU(g)
would give different results when applied to the original genotype
scores X and its top PCs PL, respectively.Simulation Set-ups
We conducted extensive simulation studies to evaluate and
compare the performance of the aSPUpath test with several alter-
native methods. Our general set-ups were similar to those (set-ups
A–D) in Chen et al.14 except that we simulated SNPs, not PCs
(called eigenSNPs therein) of SNPs, to mimic real data. Specifically,
set-up Awas the null case with no causal SNP, while the other three
set-ups contained causal SNPs in 1, 5, and 10 genes, respectively.
We considered one pathway containing 20 genes, each of which
might contain 1–20 SNPs, or 3–100 SNPs; there was at most one
causal SNP inside each gene. To cover possible situations with
more than one causal SNP inside a gene, we added set-ups B0–D0,
in which we randomly selected 1–3 causal SNPs in a gene. Further-
more, to mimic real pathways as in KEGG, we also considered
cases E and F with 40 and 80 genes, respectively, in a pathwayThwhile all other aspects were similar to set-up D0. The SNPs inside
each gene might or might not be correlated whereas the SNPs
from different genes were always independent, and the causal
SNPs might or might not be included in the data.
The simulated genotypes were generated as in Wang and
Elston.29 First, we generated a latent vector Z ¼ (Z1,.,Zk)0 from
a multivariate Normal distribution with a first-order auto-regres-
sive (AR1) covariance structure: CorrðZi;ZjÞ ¼ rjijj between any
latent components i and j; r ¼ 0 and r > 0 randomly chosen
from a uniform distributionU(0, 0.8) were used to generate (neigh-
boring) SNPs in linkage equilibrium and in linkage disequilibrium
(LD), respectively. The number of SNPs inside each gene, kg, was
randomly chosen between 1 and 20, or between 3 and 100. Sec-
ond, the latent vector was dichotomized to yield a haplotype
with MAFs each randomly selected uniformly between 0.05 and
0.4 for CVs or between 0.001 and 0.01 for RVs. Third, we com-
bined two independent haplotypes and obtained genotype data:
Xi ¼ (Xi1,.,Xik)0 for subject i. Fourth, for a non null case, the first
SNP inside the first k1 ¼ 1 or 5 or 10 genes, corresponding to set-
ups B–D, was chosen to be causal with bj ¼ logOR s 0, and all
other bj ¼ 0; we also tried set-ups B0–D0, E, and F with 1–3
randomly chosen causal SNPs. For the null case, all bj ¼ 0.
Fifth, the disease status Yi of subject i was generated from the
logistic regression model (Equation 1). We used b0 ¼ log(0.05 /
0.95) for a 5% background disease probability; that is,
PrðYi ¼ 1jXi ¼ 0Þ ¼ 0:05. Sixth, as in a case-control study, we
sampled n/2 ¼ 500 cases and n/2 ¼ 500 controls in each dataset.
Throughout the simulations, we fixed the test significance level
at a ¼ 0.05. We used the R package SNPath implementing GRASS
and Plink;14 we implemented other methods in R package aSPU.
Because the program for Plink was quite slow, we ran only 100 in-
dependent replicates for Plink, but 1,000 replicates for others in
each set-up.Results
Simulation Results for CVs
For comparison, we included the SSU (i.e., SPU(2)) and
UminP tests; the former is equivalent to a global
pathway-based test of Goeman et al.6 as shown in Pan,30
and the latter is the most popular single SNP-based test
in GWASs. The UminP test often performed similarly to
SPU(N) (data not shown).
Type I Error
As shown in Table 1, it appears that each test could control
its type I error rate satisfactorily around or within 0.05.
Comparison of the aSPUpath Test with Other Tests
We first consider set-up B, an extreme scenario that is least
favorable to pathway or SNP set analysis: because there wase American Journal of Human Genetics 97, 86–98, July 2, 2015 89
A B
C D
Figure 1. Empirical Power for Simulation
Set-up B with a Pathway of 20 Genes
One gene included one causal SNP.
(A and C) Each gene contained 1–20 inde-
pendent (A) or correlated (C) SNPs.
(B) Each gene contained 3–100 indepen-
dent SNPs.
(D) Each gene contained 1–20 correlated
SNPs and the causal SNP was excluded in
analysis.only one causal SNP, single SNP-based analysis as imple-
mented in the UminP test was expected to be most
powerful, which was confirmed as shown in Figure 1;
GATES-Simes also achieved the highest power as UminP.
Nevertheless, the aSPU and aSPUpath tests performed simi-
larly and were the next most powerful. As shown in
Figure 1A with about 200 independent SNPs, besides
UminP/GATES-Simes and aSPU/aSPUpath, Plink was
most powerful, closely followed by HYST, then by SSU,
and finally GRASS. Figure 1B shows that, with about
1,000 independent SNPs, the aSPU and aSPUpath tests
showed even a more striking advantage over the other
pathway- or SNP set-based tests except GATES-Simes, sug-
gesting the former two’s (and the latter four’s) robustness
(and lack of robustness) to an increasing number of
SNPs. In particular, the performance of SSU deteriorated
with its power close to that of GRASS. Figure 1C shows
that, with about 200 correlated SNPs (with the causal
SNP included), the power trend was similar to that with
200 independent SNPs, though GRASS performed better
than Plink and SSU with smaller ORs. As shown in90 The American Journal of Human Genetics 97, 86–98, July 2, 2015Figure 1D, with about 200 correlated
SNPs with the causal SNP excluded,
again we found GATES-Simes and
UminP, closely followed by the aSPU
and aSPUpath tests, then by HYST,
to be the top performers, while the
other three tests were similarly low
powered.
In set-up C with five causal SNPs
(Figure 2), again the aSPU and
aSPUpath tests performed similarly
and now they had an edge over the
UminP test, especially for smaller
ORs, since the latter uses only the sin-
gle SNP with the strongest signal
while ignoring the signals from other
four causal SNPs. HYST also per-
formed well, especially for large ORs,
and the power of GATES-Simes was
close to or slightly higher than that
of the UminP test. However, differing
from set-up B, we notice that the SSU
test and Plink performed similarly,
shown in Figures 2A and 2C, and
one wasmore powerful than the otherin Figures 2B and 2D, respectively. Figure 2D showed that,
with the five causal SNPs excluded, GRASS could perform
well when the causal effect size was small (and the power
was low).
Now consider a case favoring pathway or SNP set anal-
ysis in set-up D with ten causal SNPs (Figure 3). The
aSPUpath test was the sole winner, having an edge over
the aSPU test; in particular, the two tests could be much
more powerful than the UminP test and GATES-Simes,
although HYST performed well for large effect sizes. As
shown in Figures 3A and 3C, even the SSU test was much
more powerful than the UminP test, confirming the
advantage of combining information across multiple
causal SNPs. On the other hand, in Figure 3B with
about 1,000 SNPs, GATES-Simes, UminP, and Plink were
tied (after aSPUpath, aSPU, and HYST) as the next tier
of the most powerful, followed by SSU, then by GRASS;
the low power of SSU test was due to its non-robustness
to a large number of non-associated SNPs: it did not
down-weight enough the larger number of non-associated
SNPs; in contrast, the two adaptive tests, aSPU and
A B
C D
Figure 2. Empirical Power for Simulation
Set-up C with a Pathway of 20 Genes
Five genes each included one causal SNP.
(A and C) Each gene contained 1–20 inde-
pendent (A) or correlated (C) SNPs.
(B) Each gene contained 3–100 indepen-
dent SNPs.
(D) Each gene contained 1–20 correlated
SNPs and the causal SNP was excluded in
analysis.aSPUpath, did not suffer much from the presence of a
large number of non-associated SNPs. GRASS could beat
Plink when the causal effect size was small with (Figures
3A and 3C) or without (Figure 3D) the presence of the
causal SNPs.
In all the above three situations, each gene contained
either no or only one causal SNP, which might be too
restrictive. To cover possible situations with more than
one causal SNP inside a gene, we considered set-ups
B0–D0, in which we randomly selected 1–3 causal SNPs in
1, 5, and 10 genes, respectively (while other genes con-
tained no causal SNPs). The main results remained the
same as before except the following as shown in Figure 4
for set-up D0. First, there was a larger power advantage of
the aSPUpath over the aSPU test for a larger number of
SNPs (Figure 4B). Second, there was improved performance
of GRASS: for example, for small effect sizes, GRASS was
consistently more powerful than Plink, though it was still
outperformed by aSPUpath. It is clear that GATES-Simes
behaved like, albeit a little more powerful than, the UminP
test, and HYST was more powerful than the other two but
less powerful than aSPUpath.The American Journal of HTo mimic KEGG pathways, most of
which contain more than 20 genes
(e.g., Table 4), we considered two set-
ups similar to set-up D0 but with 40
or 80 genes in each pathway and
each gene with 1–20 correlated SNPs.
As shown in Figure 5, aSPUpath re-
mained themost powerful inmost sit-
uations, especially with relatively
small ORs as in typical GWASs
for complex traits, under which
GRASS performed second best. Again,
GATES-Simes performed similarly as
the UminP test, and HYST lost power
as the number of the non-associated
genes in the pathway increased.
In summary, we found that the
aSPUpath and aSPU tests were much
more powerful than pathway-based
GRASS, HYST, and Plink, and the
SSU test for SNP set analysis, across
all the simulation set-ups considered.
In the presence of multiple causal
SNPs or of multiple genes containingcausal SNPs, as anticipated for pathway analysis, they
also outperformed the single SNP-based UminP test, which
often operated like GATES-Simes; between the two
adaptive tests, the aSPUpath test had an edge over the
aSPU test in some situations, especially for a larger number
of non-associated SNPs and for casual SNPs with small
effect sizes.
Comparison of the aSPUpath Test with Its Other
Variants
For set-up B with only one causal SNP, the single-gene-
based aSPU and pathway-based aSPU tests had almost
identical power and were much more powerful than the
PC-based aSPU test. The reason was the following. First,
because there was only one single causal SNP, a single-
gene-based approach would not lose power as compared
to a pathway-based approach aiming to combine informa-
tion across multiple genes; at the same time, a pathway-
based approach in general would not gain either under
this situation. Second, note that the aSPU test could
realize effective SNP selection by adaptively choosing the
tuning parameter g to down-weight non-associated SNPs;uman Genetics 97, 86–98, July 2, 2015 91
A B
C D
Figure 3. Empirical Power for Simulation
Set-up D with a Pathway of 20 Genes
Ten genes each included one to three
causal SNPs.
(A and C) Each gene contained 1–20 inde-
pendent (A) or correlated (C) SNPs.
(B) Each gene contained 3–100 indepen-
dent SNPs.
(D) Each gene contained 1–20 correlated
SNPs and the causal SNP was excluded in
analysis.however, each PC is a linear combination of all the SNPs, a
mixture of both associated and non-associated SNPs, hin-
dering the ability of the PC-based aSPU test to select
SNPs effectively.
For set-up C with five causal SNPs, the pathway-based
aSPU test was more powerful than the gene-based aSPU
test, and the PC-based aSPU test was still the least powerful.
For set-up D with ten causal SNPs, the pathway-based
aSPU test was by far the most powerful. For 200 SNPs,
the PC-based aSPU test was more powerful than the sin-
gle-gene-based aSPU; however, with about 1,000 SNPs,
the single-gene-based aSPU was more powerful than the
PC-based aSPU, presumably due to the fact that each PC
contained too many non-associated SNPs, diluting the
association effects.
As in GRASS, we also tried to first construct gene-specific
SPU test statistics before combining them across a pathway
but did not find it working better than the simple
aSPUpath test discussed here.
In summary, we found that overall our proposed
aSPUpath test performed better than the single-gene-based
aSPU and PC-based aSPU tests.92 The American Journal of Human Genetics 97, 86–98, July 2, 2015Incorporating Prior Knowledge by
Weighting
As discussed earlier, our proposed
method can incorporate biological
knowledge or prior data on the
likelihood of SNPs and genes being
functional through weighting them
differentially. We did a preliminary
study to explore the use of informa-
tive weighting in set-up D with ten
genes, each containing one causal
SNP and with a total of about 200
correlated SNPs. We applied our pro-
posed test with wg ¼ 1, but with
wG ¼ 1 or wGs 1 to assess the effects
of some correctly specified and some
mis-specified gene weights (while
the effects of SNP weighting could
be explored similarly). We generated
wG,g ~ U (0.2, 0.6), a uniform distribu-
tion between 0.2 and 0.6, for genes
containing no causal SNPs, but for
other genes (containing causal SNPs)wG,g ~ U (0.2 þ d, 0.6 þ d) for several values of d R 0.
Increasing values of d reflected increasing informativeness
of the weights, while d¼ 0 represented completely random
and non-informative weighting. Note that, with the
overlapping weights for the genes containing causal SNPs
and for those without any causal SNP, although the
weights might be informative, strictly speaking they
were mis-specified. As shown in Table 2, it is clear that
our proposed aSPUpath test was most powerful; its
weighted version was robust to mis-specified and
completely random weights (with d ¼ 0) with only small
power loss, while gaining higher power with more infor-
mative weights.
Simulation Results for RVs
With the increasing availability of sequencing data, it has
become more important and urgent to develop and apply
pathway-based analysis of RVs; there have been few such
studies. For this purpose, we did a simulation study to
assess the performance and show the potential of our pro-
posed test for pathway analysis of RVs. To save space,
we present results only for a simulation set-up similar to
A B
C D
Figure 4. Empirical Power for Simulation
Set-up D0 with a Pathway Containing 20
Genes
Ten genes each included one to three
causal SNPs.
(A and C) Each gene contained 1–20 inde-
pendent (A) or correlated (C) SNPs.
(B) Each gene contained 3–100 indepen-
dent SNPs.
(D) Each gene contained 1–20 correlated
SNPs and the causal SNP was excluded in
analysis.set-up D: a pathway contained 20 genes, 0 or 10 of which
each contained one causal RV among 1–20 RVs for the null
or non null cases, respectively. The MAFs for the RVs were
randomly drawn between 0.1% and 1% for the controlA B
The American Journal of Hsamples. We considered both inde-
pendent and correlated RVs within
each gene.
For comparison, we also included
several existing popular or competi-
tive tests. In particular, we included
the Sum (i.e., SPU(1)) as a representa-
tive burden test, the SSU (i.e.,
SPU(2)) test that was shown by Basu
and Pan31 to be competitive and
closely related to several other associ-
ation tests such as C-alpha test32 and
kernel machine regression or SKAT,33
and three adaptive tests that appeared
recently, a kernel-based adaptive
clustering (KBAC) test,34 a p value
weighted sum test (PWSU),35 and
an estimated regression coefficient
(EREC) test.36
As shown in Table 3, all the
methods seem to have type I error
rates around the nominal level
of 0.05.As shown in Figure 6, the relative performance of the
various tests did not strongly depend on whether there
were within-gene correlations among the RVs. Clearly,
the aSPUpath test was the most powerful, closely followedFigure 5. Empirical Power for Simulation
Set-ups E and F with a Pathway Contain-
ing 40 and 80 Genes, Respectively
Ten genes each included 1–3 causal SNPs,
and each gene contained 1–20 correlated
SNPs. Set-up E with a pathway of 40 genes
(A) and set-up F with a pathway of 80 genes
(B) are shown.
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Table 2. Empirical Type I Error logOR¼ 0 and Power at logORs 0 of Various Tests for about 200 Correlated SNPs in a 20-Gene Pathway for
Set-up D
logOR
aSPUpath
GRASS Plink aSPU SSU UminP GATES-Simes HYSTwG ¼ 1 d ¼ 0 d ¼ .1 d ¼ .2 d ¼ .3 d ¼ .4
0 .054 .052 .051 .050 .048 .044 .064 .05 .048 .040 .062 .050 .042
0.15 .400 .397 .430 .468 .489 .517 .216 .13 .321 .272 .190 .223 .289
0.2 .701 .656 .713 .747 .769 .791 .360 .27 .607 .492 .353 .443 .597
0.25 .900 .873 .907 .926 .931 .936 .546 .51 .859 .763 .632 .738 .894by the usual aSPU test, then followed by the SSU test, then
GRASS, SKAT, and EREC tests. Although the SSU and SKAT
are closely related, because SKATover-weights rare variants
with smaller MAFs, which was not a correct assumption in
our simulations, here the SSU test was more powerful than
SKAT. It is worth noting that here GRASS was much more
powerful than Plink, perhaps due to the latter’s ineffective
screening on each individual RV, which contained only
a quite limited association information content with a
low MAF.
The PWST and the single RV-based UminP test per-
formed similarly. The KBAC had lowest power. Note that
here all the causal RVs had an equal association strength
(and direction), which was supposed to be ideal for the
Sum test (or other burden tests); however, due to the pres-
ence of many non-associated RVs, the Sum test and several
other adaptive tests did not perform well due to their non-
or not-so-good selection or down-weighting of the many
non-associated RVs, as discussed in Pan et al.13
Example
We applied the proposed aSPUpath test, as well as the
GRASS test, to the Wellcome Trust Case Control Con-
sortium (WTCCC) GWAS data for Crohn disease (CD
[MIM: 266600]).37 CD, a type of inflammatory bowel dis-
ease, is also considered an autoimmune disease with a
strong genetic component.3 The WTCCC GWAS dataset
contains 2,000 CD-affected case subjects and 3,000 control
subjects with a total of 500,568 SNPs. Following the
WTCCC’s quality control (QC) recommendations, we
removed subjects and SNPs that did not pass the QC
criteria, resulting in 469,612 SNPs in 1,748 case subjects
and 2,938 control subjects. We further restricted the
pathway analysis to SNPs with MAF of at least 1%. We
retrieved a total of 214 human biological pathways from
the KEGG database.1 Because a too-small pathway can
give results not too different from a gene-based analysis,
whereas the annotated function of a large pathway is likely
to be non-specific, many authors restricted their analysesTable 3. Empirical Type I Error Rates of the Tests for RVs
Set-up aSPUpath GRASS aSPU Sum
200 indep SNPs .059 .058 .060 .048
200 corr SNPs .058 .065 .047 .051
94 The American Journal of Human Genetics 97, 86–98, July 2, 2015to pathways of certain sizes. For example, Chen et al.14
and Wang et al.3 considered pathways with at least 10
genes, whereas Gui et al.9 included only pathways contain-
ing between 10 and 300 genes. Following the previous au-
thors, to facilitate interpretation of the results, we excluded
too-small (<10 genes) and too-big (>500 genes) pathways,
which resulted in 197 pathways. We obtained the genomic
coordinates of SNPs and genes according to human refer-
ence genome hg19 and assigned a SNP to a gene if it is
located within 20,000 base pairs (20 kb) upstream or down-
stream of the gene to include SNPs in regulatory regions.
A total of 64,557 SNPs were mapped to the 197 pathways
including 4,572 unique genes. The median number of
genes in a pathway was 47 with the first and third quartiles
being 27 and 76, and themedian number of SNPs in a gene
was 8 with the first and third quartiles being 4 and 17,
respectively. We employed a stage-wise permutation
strategy for both aSPUpath and GRASS tests: we first per-
formed 5,000 permutations for all pathways and then
increased to 100,000 permutations for those pathways
with p values < 0.01 in the first stage. We set the signifi-
cance threshold at 0.00025 to control the family-wise error
rate (FWER) at 0.05 based on the Bonferroni correction for
197 pathways.
Figure 7 shows the histograms of the p values across
the 197 KEGG pathways by the new method and GRASS;
their distributions were similar, though GRASS gave a
larger number of more significant p values. Overall, the
two methods gave similar and complementary results:
although many common pathways were identified to
be significant by both methods, each also detected
some unique pathways. For example, at the significance
threshold of 0.00025, aSPUpath and GRASS identified 18
and 35 significant pathways, respectively, among which
11 were common. The Spearman’s rank correlation coeffi-
cient between the p values of the two methods was 0.65.
Table 4 shows 24 KEGG pathways with p values less than
0.00001 by either method, i.e., none of the permuted test
statistics exceeded the observed one based on 100,000SSU UminP SKAT KBAC PWST EREC
.051 .068 .050 .054 .053 .048
.060 .045 .058 .048 .054 .052
A B Figure 6. Empirical Power for RVs in
Simulation Set-up D2with a Pathway Con-
taining 20 Genes
Ten genes each included one causal RV.
Each gene contained 1–20 independent
(A) or correlated (B) RVs.permutations. Interestingly, five pathways that have been
confirmed to be associated with susceptibility to CD by
meta-analysis and replication studies3,38,39 are all among
the 24 pathways. Three of them had p values less than
0.00001 by both methods. Of note, the JAK-STAT signaling
pathway (hsa04630) has been identified in quite a few pre-
vious pathway analyses.9,10,40 This pathway has 145 genes,
including IL23R (MIM: 607562) with a cluster of genome-
wide significant SNPs in the WTCCC GWAS of CD, and
nine additional genes, for example, JAK2 (MIM: 147796)
and STAT3 (MIM: 102582), which were found to be associ-
ated with CD in a large-scale meta-analysis.38 Therefore, it
is relatively easy to be identified by several pathway
analysis methods.3,9 On the other hand, two positive
control pathways, namely, NOD-like receptor signaling
pathway (hsa04621) and Chemokine signaling pathway
(hsa04062), had p values < 0.00001 only by aSPUpath,
but were not significant by GRASS (p values > 0.00025).
It is noteworthy that SNPs in NOD2 (MIM: 605956) in
the NOD-like receptor signaling pathway were the first
to be identified to be associated with CD and confer theA B C
Figure 7. Distributions of the p Values from aSPUpath and GRASS and Their Comparison
Shown are aSPUpath (A) and GRASS (B) and comparison (C).
The American Journal of Hhighest risk for CD development
among all CD-susceptibility SNPs
discovered thus far.39,41 The NOD-
like receptor signaling pathway in-
cludes not only NOD2, but also
several other CD-associated genes,
including TNF (MIM: 191160), CCL2
(MIM: 158105), and CCL7 (MIM:
158106), making it one of the most-
well-understood pathways underly-ing CD susceptibility.42 The data application here demon-
strates that our proposed aSPUpath test is a competitive
and complementary approach to the GRASS test.
For comparison, we also ran GATES-Simes and HYST,
yielding 5 and 4 pathways with p values< 0.00001, respec-
tively, all but one of which had a p value < 0.00001 by
either aSPUpath or GRASS. The only exception was
pathway hsa04622 ‘‘RIG-I-like receptor signaling;’’ the
four methods, aSPUpath, GRASS, GATES-Simes, and
HYST, gave p values of 0.00004, 0.0318, <0.00001, and
0.3050, respectively.Discussion
We have proposed a powerful adaptive test for pathway
analysis of genetic SNP data as arising in GWASs.3,4,43
Because any pathway analysis involves multiple genes,
each containing multiple SNPs, it is desirable to apply a
test that can maintain high power with a large number
of non-associated SNPs (or genes) and multiple onlyin the Log10 Scale for the WTCCC CD Data
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Table 4. Results of the WTCCC CD GWAS Data Application: KEGG Pathways with p Values < 0.00001 by Any of aSPUpath, GRASS, GATES-
Simes, and HYST
KEGG ID Pathway Names No. of Genes No. of SNPs
p Values
aSPUpath GRASS GATES-Simes HYST
hsa04630 Jak-STAT signaling pathway* 145 1,410 <0.00001 <0.00001 <0.00001 <0.00001
hsa04060 cytokine-cytokine receptor interaction* 247 2,506 <0.00001 <0.00001 <0.00001 .00001
hsa04660 T cell receptor signaling pathway* 105 1,373 <0.00001 <0.00001 .00081 .00021
hsa04310 Wnt signaling pathway 143 2,087 <0.00001 <0.00001 .00089 .00238
hsa05310 asthma 27 271 <0.00001 <0.00001 .00071 .00002
hsa05330 allograft rejection 34 466 <0.00001 <0.00001 .00089 <0.00001
hsa05414 dilated cardiomyopathy (DCM) 89 2,605 <0.00001 <0.00001 .00382 .02188
hsa05416 viral myocarditis 67 1,263 <0.00001 <0.00001 .00148 <0.00001
hsa04972 pancreatic secretion 93 2,187 <0.00001 .00003 .00072 .00211
hsa04621 NOD-like receptor signaling pathway* 57 502 <0.00001 .00542 <0.00001 .01012
hsa04062 chemokine signaling pathway* 174 2,714 <0.00001 .00061 .00131 .00119
hsa04810 regulation of actin cytoskeleton 201 3,347 <0.00001 .00108 .00156 .00962
hsa05131 shigellosis 60 784 <0.00001 .00434 <0.00001 .00159
hsa00230 purine metabolism 154 2,810 .00759 <0.00001 .05376 .02156
hsa04144 endocytosis 180 2,575 .00190 <0.00001 .00139 .01397
hsa04145 phagosome 136 1,469 .00101 <0.00001 .00314 .00272
hsa04270 vascular smooth muscle contraction 113 2,887 .00025 <0.00001 .00086 .00566
hsa04350 TGF-beta signaling pathway 82 831 .00080 <0.00001 .00060 .01381
hsa04514 cell adhesion molecules (CAMs) 122 3,312 .00120 <0.00001 .00311 .00043
hsa04612 antigen processing and presentation 63 543 .00129 <0.00001 .00146 .00016
hsa04650 natural killer cell mediated cytotoxicity 124 1,464 .00199 <0.00001 .02586 .00336
hsa04672 intestinal immune network for IgA production 45 393 .00073 <0.00001 .00105 .00009
hsa04940 type I diabetes mellitus 39 714 .00031 <0.00001 .00102 <0.00001
hsa05332 graft-versus-host disease 33 440 .00036 <0.00001 .00086 .00001
hsa04622 RIG-I-like receptor signaling pathway 65 474 .00004 .0318 <0.00001 .30502
Asterisks (*) indicate positive control pathways.weakly associated SNPs (or genes), an ideal case for our pro-
posed test. On the other hand, because the genes in a
pathway can contain different numbers of SNPs, to avoid
undue influence from a large (or small) gene, we modify
the tests to take account of varying gene lengths. Our pro-
posed test introduces two parameters (g and gG) to achieve
the objective. For example, if there are only few genes,
each containing many associated SNPs (e.g., due to LD),
a large value of g and a small value of gG would yield a
more powerful test; because the truth is unknown, we
use data to adaptively estimate their optimal values. The
adaptivity of the proposed test at the gene level and/or at
the SNP level is missing from many existing tests for
pathway or SNP set analysis, such as the SSU and SKAT
tests. As supported by our numerical examples, the pro-
posed test can gain power in many situations and serve
as a tool complementary to existing methods like GRASS.96 The American Journal of Human Genetics 97, 86–98, July 2, 2015Our proposed test is general and applicable to CVs or
RVs. It can be modified, e.g., via suitable weighting on
SNPs, for analysis of both CVs and RVs, as shown for the
SSU test in Basu and Pan.31 In addition, we can also intro-
duce some weights at the gene and SNP levels to incorpo-
rate biological knowledge onwhich genes or SNPs aremore
likely to be causal. We have focused on testing on a single
pathway; an alternative is to take account of possible over-
lapping or hierarchical structures of some pathways as
discussed in Schaid et al.12 These topics warrant future
investigation.
Finally, we note that our proposed approach is in the
category of ‘‘self-contained tests,’’ not ‘‘competitive tests,’’
because the null hypothesis to be tested here fits the
former better than the latter: we are interested in detecting
any pathways with any SNPs associated with a trait, not in
detecting ones that are over-enriched with associated
SNPs. Furthermore, as argued by Goeman and Buhl-
mann,44 the same test on the former is necessarily more
powerful than on the latter. Following Zhou et al.,45 we
can extend our aSPUpath to competitive testing. Our
goal also differs from that of Newton et al.,46 which goes
beyond only identifying significant pathways, but also
aims to uncover the common theme shared among the
identified significant pathways.Acknowledgments
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